Edition:
United States

Gemphire Therapeutics Inc (GEMP.OQ)

GEMP.OQ on NASDAQ Stock Exchange Global Market

1.01USD
18 Jan 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.01
Open
$1.05
Day's High
$1.05
Day's Low
$0.96
Volume
20,090
Avg. Vol
38,033
52-wk High
$11.41
52-wk Low
$0.57

Latest Key Developments (Source: Significant Developments)

Gemphire Therapeutics Q3 Loss Per Share $0.43
Thursday, 8 Nov 2018 04:01pm EST 

Gemphire Therapeutics Inc ::GEMPHIRE THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.43.Q3 EARNINGS PER SHARE VIEW $-0.47 -- THOMSON REUTERS I/B/E/S.MADE SIGNIFICANT ADJUSTMENTS TO OUR HEADCOUNT AND CASH BURN TO EXTEND OUR CASH RUNWAY INTO AT LEAST Q4 OF 2019.AT SEPTEMBER 30, 2018, COMPANY HAD CASH AND CASH EQUIVALENTS OF APPROXIMATELY $23.8 MILLION.BELIEVES THAT CASH ON HAND WILL BE SUFFICIENT TO FUND OPERATIONS INTO AT LEAST Q4 OF 2019.  Full Article

Gemphire Therapeutics Reports Q2 Loss Per Share Of $0.47
Monday, 13 Aug 2018 04:01pm EDT 

Aug 13 (Reuters) - Gemphire Therapeutics Inc ::GEMPHIRE THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.47.Q2 EARNINGS PER SHARE VIEW $-0.55 -- THOMSON REUTERS I/B/E/S.AT JUNE 30, CO HAD CASH AND CASH EQUIVALENTS OF ABOUT $28.0 MILLION.SAYS IT HAS "SUFFICIENT" RESOURCES TO FUND OPERATIONS INTO Q4 OF 2019.  Full Article

Gemphire Therapeutics Reports Q1 Loss Per Share Of $0.58
Tuesday, 8 May 2018 04:01pm EDT 

May 8 (Reuters) - Gemphire Therapeutics Inc ::GEMPHIRE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.58.Q1 EARNINGS PER SHARE VIEW $-0.59 -- THOMSON REUTERS I/B/E/S.TOP-LINE RESULTS FROM INDIGO-1 PHASE 2B TRIAL IN SHTG ARE TARGETED FOR Q2 2018 FOLLOWING COMPLETION OF ENROLLMENT IN Q1.  Full Article

Gemphire Therapeutics Reports Qtrly Loss Per Share $0.63‍​
Thursday, 15 Mar 2018 04:01pm EDT 

March 15 (Reuters) - Gemphire Therapeutics Inc ::GEMPHIRE THERAPEUTICS REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS.REMAINS ON TRACK TO REPORT TOP-LINE RESULTS FROM STUDY IN Q2 OF 2018.QTRLY LOSS PER SHARE $0.63‍​.Q4 EARNINGS PER SHARE VIEW $-0.69 -- THOMSON REUTERS I/B/E/S.  Full Article

Gemphire Announces Pricing Of $22 Mln Public Offering Of Common Stock
Thursday, 8 Feb 2018 09:00am EST 

Feb 8 (Reuters) - Gemphire Therapeutics Inc ::GEMPHIRE ANNOUNCES PRICING OF $22 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 3.14 MILLION COMMON SHARES PRICED AT $7.00PER SHARE.  Full Article

Gemphire Announces Proposed Public Offering Of Common Stock
Wednesday, 7 Feb 2018 04:31pm EST 

Feb 7 (Reuters) - Gemphire Therapeutics Inc ::GEMPHIRE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.GEMPHIRE THERAPEUTICS INC - ‍COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF CO'S COMMON STOCK​.  Full Article

Gemphire Therapeutics Announces Start Of First Nash Proof-Of-Concept Clinical Trial
Thursday, 21 Dec 2017 06:00am EST 

Dec 21 (Reuters) - Gemphire Therapeutics Inc ::GEMPHIRE THERAPEUTICS ANNOUNCES INITIATION OF ITS FIRST NASH PROOF-OF-CONCEPT CLINICAL TRIAL AND ITS DIFFERENTIATED NASH PROGRAM.GEMPHIRE THERAPEUTICS INC - NASH PROGRAM EXPECTED TO BE PHASE 2B READY BY YEAR-END 2018.GEMPHIRE THERAPEUTICS INC - PLANS TO LAUNCH A SECOND PHASE 2A PROOF-OF-CONCEPT TRIAL IN NASH EARLY IN 2018.  Full Article

Gemphire Therapeutics reports qtrly loss of $0.82‍​/shr
Monday, 13 Nov 2017 09:05am EST 

Nov 13 (Reuters) - Gemphire Therapeutics Inc :Gemphire Therapeutics Inc qtrly loss per share $0.82‍​.  Full Article

Gemphire announces plans to advance gemcabene into phase 3 clinical development
Tuesday, 19 Sep 2017 04:01pm EDT 

Sept 19 (Reuters) - Gemphire Therapeutics Inc :Gemphire announces plans to advance gemcabene into phase 3 clinical development.Gemphire Therapeutics Inc - ‍End of phase 2 meetings planned for early 2018​.Says gemcabene successfully achieved primary endpoint in two recently completed phase 2B studies.Gemphire Therapeutics - Results from all 20 clinical studies in 956 patients were exposed to gemcabene have demonstrated gemcabene is well tolerated and safe​.Gemphire-New analysis shows 600 mg of gemcabene reduced ldl-c by 21% in hypercholesterolemic patients, by 25% in mixed dyslipidemic patients in trials.Gemphire - Also plans to develop gemcabene as monotherapy or as add-on therapy to diet and other lipid lowering therapies for treatment of SHTG.  Full Article

Gemphire Therapeutics Inc files mixed shelf of up to $175 million - SEC filing ‍​
Friday, 1 Sep 2017 04:53pm EDT 

Sept 1 (Reuters) - Gemphire Therapeutics Inc :Gemphire therapeutics inc files mixed shelf of up to $175 million - SEC filing ‍​.  Full Article